CG Oncology Inc (CGON) reported financial results for the third quarter of fiscal 2025, aligning with analyst expectations. The company's earnings per share (EPS) stood at $-0.57, matching the consensus estimate of $-0.57. Revenue was reported at $0.0 billion, consistent with expectations.
This update provides insight into CG Oncology's recent operational performance and financial health. Meeting analyst estimates suggests that the company's performance is in line with market forecasts.
CG Oncology, a clinical biopharmaceutical company based in Irvine, California, focuses on developing bladder-sparing therapies for patients with bladder cancer. Its product candidate, cretostimogene grenadenorepvec (cretostimogene), is currently in clinical development for treating non-muscle invasive bladder cancer (NMIBC). The company’s BOND-003 trial is in Phase III, assessing the safety and efficacy of cretostimogene in high-risk BCG-unresponsive NMIBC as a monotherapy. Additionally, the CORE-001 trial is a Phase II study evaluating cretostimogene alongside BCG-unresponsive NMIBC, while PIVOT-006 is a Phase III trial investigating adjuvant cretostimogene for intermediate-risk NMIBC following transurethral resection of bladder tumors (TURBT).
The company will host its earnings conference call at 8:00 AM ET to discuss these results and provide further insights into business performance. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter's performance and future outlook.